Walleye Capital’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-119,857
| Closed | -$2.98M | – | 2192 |
|
|
2025
Q1 | $2.98M | Buy |
119,857
+72,014
| +151% | +$1.79M | 0.01% | 496 |
|
|
2024
Q4 | $901K | Buy |
+47,843
| New | +$901K | ﹤0.01% | 966 |
|
|
2024
Q2 | – | Sell |
-2,179
| Closed | -$63.7K | – | 2891 |
|
|
2024
Q1 | $63.7K | Sell |
2,179
-6,404
| -75% | -$187K | ﹤0.01% | 2094 |
|
|
2023
Q4 | $290K | Buy |
+8,583
| New | +$290K | ﹤0.01% | 1360 |
|
|
2023
Q1 | – | Sell |
-109,171
| Closed | -$4.22M | – | 2564 |
|
|
2022
Q4 | $4.22M | Buy |
109,171
+1,334
| +1% | +$51.5K | 0.08% | 285 |
|
|
2022
Q3 | $5.74M | Buy |
107,837
+69,678
| +183% | +$3.71M | 0.11% | 191 |
|
|
2022
Q2 | $2.23M | Sell |
38,159
-96,868
| -72% | -$5.65M | 0.06% | 322 |
|
|
2022
Q1 | $10.3M | Buy |
135,027
+19,930
| +17% | +$1.52M | 0.28% | 66 |
|
|
2021
Q4 | $6.93M | Buy |
115,097
+24,315
| +27% | +$1.46M | 0.22% | 91 |
|
|
2021
Q3 | $5.08K | Sell |
90,782
-3,636
| -4% | -$204 | 0.14% | 81 |
|
|
2021
Q2 | $5.73K | Buy |
94,418
+54,056
| +134% | +$3.28K | 0.2% | 65 |
|
|
2021
Q1 | $2.83K | Sell |
40,362
-4,380
| -10% | -$307 | 0.16% | 90 |
|
|
2020
Q4 | $2.68K | Buy |
+44,742
| New | +$2.68K | 0.18% | 82 |
|
|
2020
Q2 | – | Sell |
-5,280
| Closed | -$177K | – | 741 |
|
|
2020
Q1 | $177K | Buy |
5,280
+5,080
| +2,540% | +$170K | 0.04% | 304 |
|
|
2019
Q4 | $9K | Buy |
+200
| New | +$9K | ﹤0.01% | 598 |
|
|
2019
Q3 | – | Sell |
-2,576
| Closed | -$112K | – | 866 |
|
|
2019
Q2 | $112K | Buy |
+2,576
| New | +$112K | 0.01% | 234 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 292 |
|